Nasdaq · CIK 0001889109
BLTE BELITE BIO, INC
Insider trading from SEC Form 4. Last filing 8 d ago. Close $154.49 on Oct 9, 2026, +97% from the 52-week low and -20% from the high.
BELITE BIO, INC (BLTE) has 32 SEC Form 4 filings on file from 5 insiders, the latest filed on Oct 5, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 3 open-market sells worth $32M, net -$32M.
25 open-market trades have been scored at BLTE. The newest: Hendrik Peter Scholl (Chief Medical Officer) sold $83k of stock on Oct 1, 2026, filed Oct 5, 2026, scored 4 (weak), under a 10b5-1 plan. The largest of the 25 shown: Yu-Hsin Lin (Chief Executive Officer) sold $19M on Sep 4, 2026, scored 58 (moderate), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Sep 4, 2026.
BLTE closed at $154.49 on Oct 9, 2026, 97% above its 52-week low and 20% below its 52-week high.
12 Form 144 notices of planned sales are on file, the latest filed Oct 17, 2025.
Last 90 days
Net insider value
-$32M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$32M by 3 insiders
Insiders on file
5
with a Form 4 at this company
Price and insider trades, last year
BLTEOct 9, 2026 · close 154.49
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BELITE BIO, INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 4Weak | Hendrik Peter Scholl Chief Medical Officer sell | $83k 500 shares | -3% | +122% from low-16% from high | |
| 55Moderate | Hao-Yuan Chuang Chief Financial Officer sell | $13M 67,395 shares | -72% | - | |
| 58Moderate | Yu-Hsin Lin Chief Executive Officer sell | $19M 100,435 shares | -59% | - | |
| 50Moderate | Hendrik Peter Scholl Chief Medical Officer sell | $1.5M 10,000 shares | -40% | +157% from low-23% from high | |
| 50Moderate | Hendrik Peter Scholl Chief Medical Officer sell | $1.4M 10,000 shares | -29% | +143% from low-27% from high | |
| 25Weak | Nathan L. Mata Chief Scientific Officer sell | $102k 666 shares | -100% | +175% from low-18% from high | |
| 26Weak | Nathan L. Mata Chief Scientific Officer sell | $154k 1,000 shares | -60% | +175% from low-18% from high | |
| 16Weak | Nathan L. Mata Chief Scientific Officer sell | $156k 1,000 shares | -38% | +172% from low-19% from high | |
| 16Weak | Nathan L. Mata Chief Scientific Officer sell | $156k 1,000 shares | -27% | +172% from low-19% from high | |
| 11Weak | Nathan L. Mata Chief Scientific Officer sell | $156k 1,000 shares | -21% | +173% from low-19% from high | |
| 11Weak | Nathan L. Mata Chief Scientific Officer sell | $157k 1,000 shares | -18% | +180% from low-16% from high | |
| 11Weak | Nathan L. Mata Chief Scientific Officer sell | $156k 1,000 shares | -15% | +172% from low-19% from high | |
| 11Weak | Nathan L. Mata Chief Scientific Officer sell | $159k 1,000 shares | -13% | +179% from low-17% from high | |
| 11Weak | Nathan L. Mata Chief Scientific Officer sell | $163k 1,000 shares | -12% | +187% from low-14% from high | |
| 11Weak | Nathan L. Mata Chief Scientific Officer sell | $160k 1,000 shares | -10% | +184% from low-15% from high | |
| 21Weak | Nathan L. Mata Chief Scientific Officer sell | $166k 1,000 shares | -9% | +189% from low-14% from high | |
| 21Weak | Nathan L. Mata Chief Scientific Officer sell | $170k 1,000 shares | -9% | +195% from low-12% from high | |
| 21Weak | Nathan L. Mata Chief Scientific Officer sell | $166k 1,000 shares | -8% | +202% from low-13% from high | |
| 21Weak | Nathan L. Mata Chief Scientific Officer sell | $164k 1,000 shares | -7% | +202% from low-13% from high | |
| 21Weak | Nathan L. Mata Chief Scientific Officer sell | $160k 1,000 shares | -6% | +189% from low-17% from high | |
| 21Weak | Nathan L. Mata Chief Scientific Officer sell | $162k 1,000 shares | -7% | +203% from low-13% from high | |
| 21Weak | Nathan L. Mata Chief Scientific Officer sell | $168k 1,000 shares | -6% | +209% from low-11% from high | |
| 42Moderate | Hao-Yuan Chuang Chief Financial Officer sell | $1.1M 6,200 shares | -6% | +231% from low-5% from high | |
| 27Weak | Wan-Shan Chen director sell | $198k 1,100 shares | -11% | +231% from low-5% from high | |
| 45Moderate | Yu-Hsin Lin Chief Executive Officer sell | $1.7M 9,200 shares | -5% | +231% from low-5% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 17, 2025 | Wan Shan Chen Affiliate | 9,550 0.03% of outstanding | $1.2M | Oct 17, 2025 | $173k |
| Oct 16, 2025 | Wan Shan Chen affiliate | 1,050 0.00% of outstanding | $89k | Oct 16, 2025 | $84k |
| Oct 14, 2025 | Hao-Yuan Chuang Officer, Director | 70,054 0.21% of outstanding | $5.6M | Oct 13, 2025 | none |
| Oct 14, 2025 | Wan Shan Chen affiliate | 1,050 0.00% of outstanding | $84k | Oct 13, 2025 | none |
| Sep 18, 2025 | Yu-Hsin Lin CEO, Chairman | 96,950 0.30% of outstanding | $7.1M | Sep 18, 2025 | $72k |
| Aug 21, 2025 | Nathan L. Mata Officer | 30,000 0.09% of outstanding | $1.9M | Aug 21, 2025 | none |
| May 21, 2025 | Yu-Hsin Lin CEO, Chairman | 120,400 0.37% of outstanding | $7.8M | May 21, 2025 | $3.7M |
| Mar 19, 2025 | Nathan Mata Affiliate | 30,166 0.09% of outstanding | $2.0M | Mar 19, 2025 | none |
| Jan 2, 2025 | Hao-Yuan Chuang Officer, Director | 160,000 0.55% of outstanding | $10M | Jan 2, 2025 | $2.2M |
| Jan 2, 2025 | Yu-Hsin Lin CEO, Chairman | 162,000 0.56% of outstanding | $10M | Jan 2, 2025 | $2.2M |
| Nov 20, 2024 | Wei-Cheng Liaw affiliate | 5,999 0.02% of outstanding | $495k | Nov 20, 2024 | $300k |
| Nov 19, 2024 | Nathan Mata Affiliate | 30,000 0.10% of outstanding | $2.5M | Nov 19, 2024 | $1.4M |
Transactions
The newest 50 of 178 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -200 | $163.63 | $33k | 14,800 | 8 d ago |
| Oct 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -24 | $164.64 | $3,951 | 14,776 | 8 d ago |
| Oct 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -120 | $165.49 | $20k | 14,656 | 8 d ago |
| Oct 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -50 | $166.44 | $8,322 | 14,606 | 8 d ago |
| Oct 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -78 | $167.59 | $13k | 14,528 | 8 d ago |
| Oct 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -12 | $168.21 | $2,019 | 14,516 | 8 d ago |
| Oct 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -14 | $169.36 | $2,371 | 14,502 | 8 d ago |
| Oct 1, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd.10b5-1 | -2 | $170.02 | $340 | 14,500 | 8 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -2,635 | $180.29 | $475k | 167,934 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -1,633 | $180.16 | $294k | 91,800 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -2,587 | $181.24 | $469k | 165,347 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -2,000 | $181.05 | $362k | 89,800 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -3,413 | $182.50 | $623k | 161,934 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -2,000 | $182.49 | $365k | 87,800 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -4,955 | $183.30 | $908k | 156,979 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -3,759 | $183.27 | $689k | 84,041 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -6,252 | $184.52 | $1.2M | 150,727 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -3,569 | $184.57 | $659k | 80,472 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -4,593 | $185.34 | $851k | 146,134 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -3,872 | $185.28 | $717k | 76,600 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -7,800 | $186.32 | $1.5M | 138,334 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -4,600 | $186.35 | $857k | 72,000 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -6,200 | $187.25 | $1.2M | 132,134 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -3,900 | $187.16 | $730k | 68,100 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -3,045 | $188.26 | $573k | 129,089 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -1,900 | $188.59 | $358k | 66,200 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -8,955 | $189.34 | $1.7M | 120,134 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -6,200 | $189.22 | $1.2M | 60,000 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -600 | $190.39 | $114k | 119,534 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -1,800 | $190.63 | $343k | 58,200 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -11,080 | $191.15 | $2.1M | 108,454 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -6,200 | $191.09 | $1.2M | 52,000 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -4,209 | $192.54 | $810k | 104,245 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -3,398 | $192.40 | $654k | 48,602 | 34 d ago |
| Sep 4, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -4,602 | $193.12 | $889k | 44,000 | 34 d ago |
| Sep 4, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -8,111 | $193.13 | $1.6M | 96,134 | 34 d ago |
| Sep 8, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -2,200 | $194.28 | $427k | 41,800 | 34 d ago |
| Sep 8, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -2,400 | $194.33 | $466k | 93,734 | 34 d ago |
| Sep 8, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -4,120 | $195.60 | $806k | 37,680 | 34 d ago |
| Sep 8, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -6,090 | $195.62 | $1.2M | 87,644 | 34 d ago |
| Sep 8, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -6,058 | $196.54 | $1.2M | 81,586 | 34 d ago |
| Sep 8, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -4,475 | $196.47 | $879k | 33,205 | 34 d ago |
| Sep 8, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -8,752 | $197.36 | $1.7M | 72,834 | 34 d ago |
| Sep 8, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -4,605 | $197.23 | $908k | 28,600 | 34 d ago |
| Sep 8, 2026 | Yu-Hsin Lin Chief Executive Officer | SOpen-market sale American depositary share10b5-1 | -2,700 | $198.09 | $535k | 70,134 | 34 d ago |
| Sep 8, 2026 | Hao-Yuan Chuang Chief Financial Officer | SOpen-market sale American depositary share10b5-1 | -2,562 | $198.05 | $507k | 26,038 | 34 d ago |
| Jun 18, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd. | -96 | $143.90 | $14k | 24,904 | Jun 22, 2026 |
| Jun 18, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd. | -3,748 | $144.66 | $542k | 21,156 | Jun 22, 2026 |
| Jun 18, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd. | -4,861 | $145.43 | $707k | 16,295 | Jun 22, 2026 |
| Jun 18, 2026 | Hendrik Peter Scholl Chief Medical Officer | SOpen-market sale American depositary shareindirect: By Bioptima Ltd. | -1,199 | $146.24 | $175k | 15,096 | Jun 22, 2026 |
50 of 178 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Wan-Shan Chendirector
- Hao-Yuan ChuangChief Financial Officer
- Yu-Hsin LinChief Executive Officer
- Nathan L. MataChief Scientific Officer
- Hendrik Peter SchollChief Medical Officer
Questions about BLTE
Answered from the filings on this page, as of the latest one.
Are insiders buying BLTE?
As of Oct 5, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 3 open-market sells worth $32M by 3 insiders at BELITE BIO, INC in the last 90 days, net -$32M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade BLTE on the open market?
Hendrik Peter Scholl (Chief Medical Officer) sold $83k of BLTE on Oct 1, 2026 and filed the Form 4 on Oct 5, 2026. InsiderTell scored 4 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at BELITE BIO, INC?
5 people have filed a Form 4 at BELITE BIO, INC, among them Wan-Shan Chen (director), Hao-Yuan Chuang (Chief Financial Officer), Yu-Hsin Lin (Chief Executive Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.